

Basilea Pharmaceutica

Steady as she goes

FY16 results update

Pharma & biotech

Basilea reported a solid set of 2016 numbers ahead of guidance, driven by higher than expected product sales in H216 combined with lower than expected operating costs. Cresemba (for invasive mould infections), in particular, continues to pick up momentum both in the EU and the US through US partner Astellas. Zevtera's US pivotal Phase III clinical trial programme for bacterial infections remains on track to initiate in mid-2017. Multiple distribution and commercialisation agreements signed in H216 should lead to international launches starting from 2018 for both products. We value Basilea at CHF1,048m or CHF97/share (excl. treasury shares).

Year end	Revenue (CHFm)	PBT* (CHFm)	EPS* (CHF)	DPS (CHF)	P/E (CHF)	Yield (%)
12/15	52.8	(61.3)	(6.07)	0.0	N/A	N/A
12/16	66.0	(50.9)	(4.69)	0.0	N/A	N/A
12/17e	88.3	(37.5)	(3.37)	0.0	N/A	N/A
12/18e	95.1	(36.5)	(3.22)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

FY16 results: Guidance beaten; still room to grow

Basilea reported total revenues of CHF66m in FY16 (+25%), including product sales of CHF7.1m (relating to the first full year in which both brands have been available in Europe), which beat guidance of CHF5m. This was due to Cresemba uptake in the EU, although Zevtera uptake remains lacklustre (we have lowered our peak sales expectations accordingly). Basilea reported CHF7.3m in royalties on \$46m of US Cresemba sales reported by Astellas. 2017 guidance for product sales and royalties (on US sales) stands at CHF15m and CHF14m respectively. In 2018 both products should benefit from international launches following the slew of distribution deals in H216; we anticipate further deals in 2017.

Mid-2017 Zevtera US clinical programme to initiate

Following the announcement of the BARDA contract (up to \$100m) to develop Zevtera for the US, Basilea has submitted the Phase III study Special Protocol Assessments (SPAs) with the FDA. Phase III trials in skin and bacteraemia (bloodstream) infections should start mid-year and a 2021 US launch date could be feasible. In terms of value, the US is the largest market for branded hospital antibiotics representing a major opportunity. We expect Basilea to look for a commercialisation partner in the US once the pivotal clinical development programme is underway.

Valuation: rNPV of CHF1,048m or CHF97/share


We have lowered our valuation to CHF1,048m (from CHF1,091m), mainly as a result of reducing our peak sales expectations for Zevtera non-US sales and rolling forward our DCF, offset by a lower net cash position. Our valuation is based on an NPV of the main portfolio of products and net cash. Cresemba, based on \$600m peak sales globally, is worth c 72% of our rNPV and underpins c 88% of the current market cap. We include Zevtera in Europe/RoW (albeit with reduced expectations), in addition to risk-adjusted contributions for the US opportunity and the earlier-stage pipeline.

1 March 2017

Price CHF86.00
Market cap CHF1016m

Net cash (CHFm) at 31 December 2016	93.6
Shares in issue*	11.8m
*Including 1m treasury shares	
Free float	90.4%
Code	BSLN
Primary exchange	SIX
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	19.2	25.4	21.1
Rel (local)	15.7	15.5	11.2
52-week high/low	CHF86.2	CHF62.0	

Business description

Basilea is a Swiss biopharmaceutical company focused on anti-infectives and oncology. Its lead products are Cresemba, an antifungal that is approved in the US and Europe, and Zevtera, an anti-MRSA broad-spectrum antibiotic, approved in Europe for pneumonia.

Next events

Zevtera initiate PIII US studies	Mid-2017
2017 half year results	10 August 2017

Analysts

Dr Susie Jana	+44 (0)20 3077 5700
Dr Daniel Wilkinson	+44 (0)20 3077 5734

healthcare@edisongroup.com

[Edison profile page](#)

Basilea Pharmaceutica is a research client of Edison Investment Research Limited

Guidance beaten – driven by Cresemba

Basilea reported a solid set of 2016 numbers ahead of guidance, driven by higher than expected product sales (Cresemba for mould infections and Zevtera/Mabelio for bacterial infections). Total revenues were reported at CHF66m for FY16 (+25%), including product sales of CHF7.1m, which beat guidance of CHF5m. In H116, cumulative product sales were reported as CHF1.9m, indicating that sales in the second half amounted to CHF5.2m, which we believe reflects stronger than expected growth in Cresemba sales. Zevtera sales remain lacklustre; as mentioned in previous reports, sales of antibiotics such as Zevtera/Mabelio in particular take time to build post launch, given the requirement for regional reimbursement across Europe and the need to be added to individual hospital formularies. Basilea reported CHF7.3m in royalties on \$46m of US Cresemba sales; Astellas has guided \$56m in sales for the financial year 1 April 2016 to 31 March 2017. We note that guidance has increased from the \$45m pegged at Basilea's interim results, which reflects favourably on Cresemba's US momentum to date in its second year on the market.

Basilea reported an operating loss of CHF43.9m in FY16, beating guidance (CHF48-60m). R&D expenses were lower than expected (as a result of a decrease in pre-launch costs booked in R&D in previous years). However, with the Zevtera PIII US programme poised to start and the ongoing oncology pipeline programmes, we expect R&D expenses to increase in 2017 to CHF54.7m from CHF48.4m in 2016. We therefore forecast an operating loss of CHF33.1m. Basilea reported cash and cash equivalents of CHF289m at year end December 2016. Our financial model suggests that current cash should be sufficient to fund operations beyond 2019, even in the absence of any milestone payments.

Basilea has provided financial guidance for FY17; total product sales are expected at CHF15m, royalties on US Cresemba sales at ~CHF14m and operating loss in the region of approximately CHF3m per month on average, indicating an operating loss of ~CHF36m for the year. We anticipate a doubling in product sales to CHF14m in 2017, driven mainly by Cresemba. We expect both products to benefit from international launches in 2018 following the slew of distribution deals in H216; we anticipate further deals in 2017. However, given the slower than expected uptake for Zevtera, we have revisited our global peak sales expectations (see below) and have revised our ex-US sales estimates downwards.

Significant progress in partnering deals in 2016

Basilea made significant progress in partnering deals in 2016. Basilea's existing partnerships now cover more than 40 countries internationally, as well as the countries that Basilea is directly commercialising. The agreement with Hikma has been extended in the MENA region to cover Cresemba, in addition to the original agreement on Zevtera. Other distribution agreements signed in the year include Grupo Biotoscana (GBT) for 19 counties in Latin America and Unimedica Pharma in the Nordics (Cresemba and Zevtera). Basilea has entered a development and commercialisation partnership with Asahi Kasei Pharma (AKP) for Cresemba in Japan; AKP will oversee the clinical trial programme required for Japanese approval. Further deals should be anticipated in 2017 as Basilea looks to leverage both products globally through regionally relevant partners. According to Basilea, more than one-third of sales opportunities for novel anti-fungal agents reside in ex-US and the major European countries.

For more detail on the deals, see our note [Licensing double act](#), published on 16 September 2016.

Cresemba momentum growing in Europe and US

Basilea is commercialising Cresemba (isavuconazole, a broad-spectrum antifungal drug) alone in key European markets (including the UK, Germany, Italy and France) through a fee-for-service contract salesforce via an agreement with Quintiles. We believe that Cresemba accounts for ~85% of the CHF7.1m product sales reported in 2016. In the US, licence partner Astellas launched the product in April 2015 for treating both invasive aspergillosis and invasive mucormycosis. Basilea reported CHF7.3m in royalties on \$46m of US Cresemba sales. Astellas has guided \$56m in sales for the financial year 1 April 2016 to 31 March 2017. We note that guidance has increased from the \$45m pegged at Basilea's interim results. The Swissmedic review of the marketing authorisation for Cresemba is ongoing and expected to complete in 2017; we anticipate a launch in late 2017 or early 2018.

With broad-spectrum activity against fungal moulds in addition to safety and other benefits (including fewer drug interactions and once-daily dosing) over current standard treatments, we believe Cresemba could have a unique position in this growing market, even in the face of increasing genericisation. We note that the [latest guideline](#) issued by the European Conference on Infections in Leukaemia (ECIL) recommends Cresemba for the first-line treatment of invasive aspergillosis in leukaemia and hematopoietic stem cell transplant patients. Specifically, it states that "isavuconazole is as effective as voriconazole with a better safety profile". The company believes that this recommendation underscores the potentially important clinical role of Cresemba in the treatment of patients with these life-threatening infections.

We forecast total Cresemba peak sales potential of \$600m, with Cresemba contributing c 72% to our valuation. We will maintain our current assumptions until we have more visibility on the start of the bridging trials in Japan and the timing of a potential launch in these newly partnered markets.

Zevtera US opportunity, BARDA contract funds US development

Zevtera uptake in Europe remains slow, as expected; sales of antibiotics such as Zevtera/Mabelio take time to build post launch, given the requirement for regional reimbursement across Europe, plus the need to be added to individual hospital formularies. We anticipate that the bulk of Zevtera's opportunity resides in its fate in the US market. In terms of value, the US represents about 70-80% of the total global market for newer-branded hospital antibiotics.

In March 2016, the Biomedical Advanced Research and Development Authority (BARDA), a division of the US Department of Health and Human Services Office, entered into a contract with Basilea for the Phase III development of Zevtera for the US market. Under the terms of the contract, Basilea will receive up to \$20m over the initial 18-month period, with an additional up to \$80m potentially due contingent on achieving predefined development milestones by BARDA over a 4.5-year period. The company has submitted the Phase III study protocols seeking agreement on SPAs with the FDA and trials should initiate mid-year (we expect three to 3.5 years duration), implying that a US 2021 launch date could be feasible, with an initial focus of bacteraemia and acute bacterial skin and skin structure infections. *Staphylococcus aureus* bacteraemia (presence of bacteria in the blood) is an indication where few antibiotics are currently approved and which the FDA considers an area of unmet need. Thus, Basilea intends to conduct a bacteraemia study to further differentiate Zevtera from available cephalosporins.

Importantly, the BARDA contract provides a path to create further value by enabling non-dilutive funding for the programme before seeking a commercialisation partner for the US market. Additionally, results from the US clinical trial programme could be used to support supplementary indications in Europe and other territories, leveraging Zevtera's potential use further.

Given the slower than expected uptake for Zevtera, we have revisited our global peak sales expectations and reduced our non US sales forecasts. We have reduced our peak sales estimates

to \$513m from \$556m, consisting of \$85m peak sales for Zevtera in Europe (for the currently approved indications) and \$428m for RoW (including \$317m for the US opportunity, which is risk-adjusted). Phase III data from the US trials, if positive, could be used to expand Zevtera's EU/RoW label to include *Staphylococcus aureus* bacteraemia and acute skin and skin structure infections indications. Our current peak sales estimates for EU/RoW do not include these indications, hence this could provide upside to our financial forecasts.

For more detail on Cresemba and Zevtera, see our note [Riding the crest of the antimicrobial wave](#) published on 23 March 2016.

Oncology pipeline assets data expected in 2018

In 2016 Basilea moved forward with its oncology pipeline. BAL101553 is a highly soluble prodrug of BAL27862, which induces tumour cell death through activation of a checkpoint important for tumour cell division. In December 2016 the company announced the expansion of the BAL101553 clinical Phase I/IIa oral formulation study to include patients with recurrent or progressive glioblastoma (brain cancer) after prior radiotherapy with or without chemotherapy.

BAL3833 is a panRAF/SRC kinase inhibitor in Phase I development in advanced solid tumours. Preclinical data suggest that BAL3833 has activity in KRAS-driven cancer models, suggesting it could have clinical utility in major tumour types beyond BRAF-driven melanoma. The Phase I dose escalation study is ongoing.

The Phase I/IIa and Phase I dose escalation studies evaluating BAL101553 and BAL3833 respectively in patients with solid tumors are due to complete by year end, with results available in H118.

Valuation: rNPV of CHF1,048m or CHF97/share

Our updated Basilea valuation is CHF1,048m (from CHF1,091m previously), primarily as a result of adjustments to our Zevtera assumptions and rolling forward our DCF, offset by a lower net cash position at end December 2016 (CHF93.6m vs CHF116m at end June 2016). Our valuation is based on an NPV analysis, which includes the main portfolio of products and net cash. Cresemba, based on \$600m peak sales, is worth ~72% of our rNPV and underpins c 88% of the current market cap. We also include Zevtera in Europe, in addition to risk-adjusted contributions for the US opportunity and the earlier-stage pipeline. Given the slower than expected uptake for Zevtera, we have reduced our peak sales estimates to \$513m from \$556m, consisting of \$85m peak sales for Zevtera in Europe (for the currently approved indications) and \$428m for RoW (including \$317m for the US opportunity, which is risk-adjusted). We have increased our probability for US Zevtera to 75% from 50% given that the US pivotal Phase III clinical trial programme for bacterial infections is on track to initiate in mid-2017. The breakdown of our valuation is shown in Exhibit 1.

Exhibit 1: Basilea rNPV summary

Product	Indication	Launch	Peak sales (\$m)	Value (CHFm)	Probability	rNPV (CHFm)	NPV/share (CHF/share*)
Cresemba (isavuconazole)	Severe fungal infections	2015 (US); 2016 (EU)	600	758.2	100%	758.2	70.2
Zevtera/Mabelio (ceftibiprole)	Severe bacterial infections	2015 (EU) 2018 (RoW); 2019 (US)	85 428	51.7 138.5	100% 75%	51.7 103.8	4.8 9.6
BAL101553	Tumour resistance	2022	500	132.6	20%	35.4	3.3
BAL3833	Tumour resistance	2023	500	68.8	15%	5.8	0.5
Net Cash/(Debt)				93.6	100%	93.6	8.7
Valuation				1,243.3		1,048.5	97.1

Source: Edison Investment Research, Basilea Pharmaceutica. *Excluding treasury shares

Financials: FY17 guidance provided

Basilea reported FY16 product sales of CHF7.1m on sales of anti-microbial agents Cresemba and Zevtera/Mabelio in Europe and royalties on US Cresemba sales of CHF7.3m. Total revenues increased 25% in FY16 (reported at CHF66.0m) vs FY15 (reported at CHF52.8m). Basilea reported contract revenues of CHF57.7m in FY16, reflecting an increase in royalty income relating to Cresemba on US sales; the company reported CHF7.3m in royalties on \$46m of US Cresemba sales. Astellas has guided \$56m in sales for the financial year 1 April 2016 to 31 March 2017. At this stage our peak sales forecasts of \$600m are unchanged, but we will be closely monitoring Cresemba's sales evolution. Conversely, as discussed above, we have decreased our peak sales expectations of Zevtera to \$513m from \$556m based on currently approved indications.

Costs and operating expenses were lower than the previous year, at CHF104.5m (FY16) vs CHF114.3m (FY15), and accounted for a large reduction in R&D costs offsetting a slight increase in SG&A and the reporting of CHF3m in the COGS line. We note that our cost of sales assumptions relate purely to cost of goods sold; this differs from Basilea's reported cost of sales, which includes manufacturing, capacity reservation, shipping and handling costs (Edison accounts for these costs in SG&A). Thus, during the launch period, cost of sales as reported by Basilea is higher than our forecast cost of sales. We forecast 2017 R&D spend of CHF54.7m; our forecasts assume that Basilea will contribute around 30% of the total \$120-150m development costs for Zevtera's US Phase III development between 2017 and 2020, with BARDA funding the rest. Future R&D spend will also depend on partnering activities for the earlier-stage assets, although we do not anticipate any deals for either BAL101553 or BAL3833 until Phase II proof-of-concept data become available.

SG&A in 2016 was CHF56.1m. Although Basilea does not explicitly split out spend on G&A and S&M, we believe underlying G&A costs are around CHF21m (evidenced by SG&A spend of CHF21.3m in 2013 when there were no S&M-related expenses). We forecast a marginal 3% increase in underlying G&A. We estimate that S&M spend in 2016 was around CHF33m for the ongoing build-out of a contract salesforce via Quintiles. We believe CHF37-39m of S&M spend should support commercialisation of both Zevtera and Cresemba in the five major European markets.

Overall, we now forecast total operating expenses of CHF116.3m in 2017 from CHF104.5m in 2016. We forecast an operating loss of CHF33.1m for FY17, which is slightly below company guidance of CHF3m average operating loss per month.

Management has confirmed financial guidance for 2017, highlighted in Exhibit 2 below, alongside our estimates for the year.

Exhibit 2: Our forecasts are in line with 2017 company guidance

	Outlook	Edison estimates
Product sales	CHF15m/year	CHF14.9m
Royalties on US sales of Cresemba	CHF14m/year	CHF13.9m
Operating expenses	CHF10m/month	CHF118.3m/year
Operating loss	CHF3m*/month	CHF33m/year

Source: Basilea Pharmaceutica, Edison Investment Research. Note: *On average. Basilea's guidance was last updated in February 2017.

Cash could be sufficient beyond 2019

Basilea reported cash and equivalents, including liquid assets, of CHF289m at year-end December 2016 compared to CHF115.8m at June 2016. This includes proceeds from the convertible bond, which we record on the balance sheet as long-term debt at CHF195m. The convertible bond is due in 2022 and has a conversion price of CHF126 (based on a 30% premium to the volume weighted average share price on 9 December 2015, which was CHF97). The coupon is 2.75%, or

CHF5.5m/year, which is paid semi-annually in arrears. Our financial model suggests current cash should be sufficient to fund operations beyond 2019, even in the absence of any milestone payments.

Exhibit 3: Financial summary

	CHF'000s	2015	2016	2017e	2018e	2019e
		US GAAP	US GAAP	US GAAP	US GAAP	US GAAP
December						
PROFIT & LOSS						
Revenue		52,825	65,984	88,343	95,123	108,744
Cost of Sales		0	(5,347)	(5,185)	(6,383)	(10,345)
Gross Profit		52,825	60,637	83,158	88,740	98,399
Research and development		(60,075)	(48,449)	(54,653)	(57,149)	(60,201)
EBITDA		(58,885)	(41,570)	(30,737)	(29,967)	(25,122)
Operating Profit (before amort. and except.)		(61,285)	(43,789)	(33,061)	(32,429)	(27,737)
Intangible Amortisation		(200)	(100)	(100)	(123)	(9)
Exceptionals		0	0	0	0	0
Other		0	0	0	0	0
Operating Profit		(61,485)	(43,889)	(33,161)	(32,552)	(27,745)
Net Interest		(35)	(7,065)	(4,425)	(4,108)	(3,649)
Profit Before Tax (norm)		(61,320)	(50,854)	(37,486)	(36,537)	(31,386)
Profit Before Tax (reported)		(61,520)	(50,954)	(37,586)	(36,660)	(31,395)
Tax		(83)	(333)	(26)	(26)	(26)
Profit After Tax (norm)		(61,403)	(51,187)	(37,513)	(36,563)	(31,413)
Profit After Tax (reported)		(61,603)	(51,287)	(37,613)	(36,686)	(31,421)
Average Number of Shares Outstanding (m)		10.1	10.9	11.1	11.4	11.6
EPS - normalised (c)		(607.22)	(469.16)	(336.93)	(321.94)	(271.26)
EPS - normalised fully diluted (CHFc)		(607.22)	(469.16)	(336.93)	(321.94)	(271.26)
EPS - (reported) (CHFc)		(6.09)	(4.70)	(3.38)	(3.23)	(2.71)
Dividend per share (CHFc)		0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		100.0	91.9	94.1	93.3	90.5
EBITDA Margin (%)		N/A	N/A	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)		N/A	N/A	N/A	N/A	N/A
BALANCE SHEET						
Fixed Assets		13,870	59,264	59,450	59,719	60,358
Intangible Assets		346	232	132	9	0
Tangible Assets		10,724	8,878	9,165	9,557	10,204
Investments		2,800	50,154	50,154	50,154	50,154
Current Assets		384,865	268,494	183,389	125,366	84,437
Stocks		9,579	14,931	10,710	8,743	8,503
Debtors		1,545	2,492	2,420	2,606	2,979
Cash		364,688	239,030	158,217	101,975	60,914
Other		9,053	12,041	12,041	12,041	12,041
Current Liabilities		(68,836)	(72,914)	(56,768)	(36,700)	(47,222)
Creditors		(68,836)	(72,914)	(56,768)	(36,700)	(47,222)
Short term borrowings		0	0	0	0	0
Long Term Liabilities		(315,043)	(289,844)	(253,723)	(239,723)	(215,333)
Long term borrowings		(194,706)	(195,466)	(195,466)	(195,466)	(195,466)
Other long term liabilities		(120,337)	(94,378)	(58,257)	(44,257)	(19,867)
Net Assets		14,856	(35,000)	(67,653)	(91,339)	(117,760)
CASH FLOW						
Operating Cash Flow		(67,780)	(70,203)	(73,711)	(49,254)	(34,123)
Net Interest		0	(7,065)	(4,425)	(4,108)	(3,649)
Tax		0	(333)	(26)	(26)	(26)
Capex		(1,009)	(1,980)	(2,650)	(2,854)	(3,262)
Acquisitions/disposals		0	0	0	0	0
Financing		(0)	1,000	0	0	0
Other		12,645	(47,837)	0	0	0
Dividends		0	0	0	0	0
Net Cash Flow		(56,143)	(126,418)	(80,813)	(56,242)	(41,061)
Opening net debt/(cash)		(226,125)	(169,982)	(43,564)	37,249	93,491
HP finance leases initiated		0	0	0	0	0
Other		0	0	0	0	0
Closing net debt/(cash)		(169,982)	(43,564)	37,249	93,491	134,552

Source: Edison Investment Research, Basilea Pharmaceutica

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Basilea Pharmaceutica and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE data is permitted without FTSE's express written consent.